Tectonic Therapeutic, Inc. (TECX): Capital Expenditures
$208.0K
Year ended 2025-12-31
$279.0K
Trailing 12 months to 2026-06-30
-8.0%
3-year compound annual growth
-29.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $208.0K | +33.3% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $156.0K | -44.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $279.0K | +4.5% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $267.0K | -89.2% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $2.46M | +109.1% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $1.18M | -25.7% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $1.58M | -13.5% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $1.83M | +378.3% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $383.0K | n/a | 2019-03-25, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $208.0K | +33.3% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $397.0K | -17.5% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $155.0K | +10.7% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $886.0K | -81.1% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $3.83M | -22.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $532.0K | -77.2% |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $1.15M | +76.3% |
Compare TECX, LXEO, VYGR, IVVD side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗